Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
16 Fevereiro 2022 - 11:00AM
Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating
in the field of oral biotherapeutics for gastrointestinal health
and beyond, today shared an oral presentation that was delivered by
Dr. Bram Verstockt during the 34th edition of the Belgian Week of
Gastroenterology on February 9, 2022.
During the oral presentation titled “Tofacitinib tissue exposure
correlates with endoscopic outcome,” lead author Dr. Verstockt
presented patient data demonstrating a significant relationship
between mucosal exposure and endoscopic improvement in patients
with moderate to severe ulcerative colitis who were treated with
tofacitinib.
“These data support the hypothesis that targeted delivery of
tofacitinib to the site of disease has the potential to improve
patient outcomes. This will be further explored in clinical trials
with PGN-600 to determine whether Progenity’s targeted approach can
increase mucosal exposure and decrease systemic exposure,” said Adi
Mohanty, Chief Executive Officer of Progenity. “With this
technology, we anticipate successful delivery of higher therapeutic
doses directly to the mucosa while avoiding current issues with
toxicity due to systemic uptake. We thank the clinical teams
responsible for this independent study, in particular those at IBD
Leuven and Amsterdam UMC, for their excellent work toward our
shared goal of better therapeutic efficacy for IBD patients.”
A replay of the presentation is available by visiting the
“Publications” section of the Progenity website.
About the Drug Delivery System (DDS) and
PGN-600Progenity’s Drug Delivery System (DDS) is an
ingestible capsule designed for targeted delivery of therapeutics
to improve treatment of inflammatory bowel disease (IBD). For the
1.8 million patients in the United States who suffer from IBD,
existing therapeutics offer less than ideal efficacy, likely
because of the challenges with safely achieving sufficient drug
levels in the affected tissues.
The DDS targeted therapeutics platform utilizes a novel approach
that could improve IBD patient outcomes by maximizing the available
dose at the site of disease while reducing systemic toxicity. Once
swallowed, the capsule is designed to autonomously identify when it
has arrived at a specific location in the gastrointestinal tract
and release a therapeutic dose at the site of disease. The DDS is
approximately the size of a “000” capsule, the size of many fish
oil capsules. It is designed to deliver a range of liquid
formulations in amounts up to 500 µL. In normal healthy volunteers,
the DDS was shown to be safe and accurate in identifying entry into
the colon. Progenity is a recipient of the Crohn’s and Colitis
Foundation IBD Ventures development grant to support development
and further clinical evaluation of the DDS platform.
Progenity is developing the PGN-600 program, which consists of
oral liquid formulation of tofacitinib delivered to the colon via
the DDS capsule, for the treatment of ulcerative colitis. The
company has shown preclinically in canines that successful targeted
delivery using PGN-600 can lead to reduced drug levels in blood and
increased drug levels in tissue at least 25 times higher along the
length of the colon as compared to the equivalent standard oral
dose. Progenity expects to initiate a phase 1 clinical trial of
PGN-600 in late 2022.
About ProgenityProgenity, Inc. is a
biotechnology company innovating in the fields of oral
biotherapeutics, gastrointestinal health, and women’s health.
Progenity applies a multi-omics approach, combining genomics,
epigenomics, proteomics, and metabolomics to its molecular testing
products and to the development of a suite of investigational
ingestible devices designed to provide precise diagnostic sampling
and drug delivery solutions. Progenity’s vision is to transform
healthcare to become more precise and personal by improving
diagnoses of disease and improving patient outcomes through
localized treatment with targeted therapies.
For more information visit www.progenity.com, or follow the
company on LinkedIn or Twitter.
Forward Looking StatementsThis press release
contains “forward-looking statements,” which statements are subject
to substantial risks and uncertainties and are based on estimates
and assumptions. All statements, other than statements of
historical facts, included in this press release are
forward-looking statements. Forward-looking statements include
statements regarding Progenity’s products under development and the
potential uses for such products in the United States and globally.
In some cases, you can identify forward-looking statements by terms
such as “if,” “may,” “might,” “will,” “objective,” “intend,”
“should,” “could,” “can,” “would,” “expect,” “believe,” “design,”
“estimate,” “predict,” “potential,” “develop,” “plan” or the
negative of these terms, and similar expressions, or statements
regarding intent, belief, or current expectations, are forward
looking statements. These statements involve known and unknown
risks, uncertainties and other factors that could cause Progenity’s
actual results to differ materially from the forward-looking
statements expressed or implied in this press release, including
Progenity’s ability to successfully develop and commercialize its
products under development, the uncertainties inherent in the
development process, such as the regulatory approval process, the
timing of regulatory filings, the ability to identify potential
partners and other matters, including the ongoing COVID-19
pandemic, that could affect sufficiency of existing cash, cash
equivalents and short-term investments to fund operations and the
availability or commercial potential of Progenity’s products, and
those risks described in “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” in Progenity’s Annual Report on Form 10-K for the year
ended December 31, 2020, filed with the SEC on March 18, 2021, and
other subsequent documents we file with the SEC, including but not
limited to Progenity’s Quarterly Reports on Form 10-Q. Progenity
claims the protection of the Safe Harbor contained in the Private
Securities Litigation Reform Act of 1995 for forward-looking
statements. Progenity expressly disclaims any obligation to update
or alter any statements whether as a result of new information,
future events or otherwise, except as required by law.
Investor ContactChuck PadalaManaging Director,
LifeSci Advisorsir@progenity.com (917) 741-7792
Media ContactKristin SchaefferCG
Lifemedia@progenity.com (858) 457-2436
Biora Therapeutics (NASDAQ:PROG)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Biora Therapeutics (NASDAQ:PROG)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024